DR-031 “Genomic characterization of metastatic urothelial carcinoma. DR-031 is an extension of DR-008”
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-031 “Genomic characterization of metastatic urothelial carcinoma. DR-031 is an extension of DR-008”
This project aims to unravel molecular mechanisms that drive the high metastatic potential of urothelial cancer.a In addition predictive markers …
DR-029 Genetische biomarkers predictief voor irinotecan respons
Irinotecan is a widely used cytostatic treatment for a broad range of tumor types. However, response is highly variable making …
DR-028 Genomic aberrations ins oft tissue sarcomas / Genomische afwijkingen in weke delen tumoren
This project aims to characterize the genetic landscape of sarcoma tumors and relate this to treatment outcome data. Improving patient …
DR-027 De rol van famacogenetica bij verworven tumorresistentie
The effect of anti-cancer drugs depends on the amount of drug that is present in the tumor cells. If these …
DR-026 The clinical significance of whole genome sequencing data in metastatic breast cancer
This project aims to create a systematic overview of the mutation landscape of metastatic breast cancer patients and identify similarities …
DR-024 Identification of non-coding mutations across cancer types
“Most studies have focused on mutations in the few percent of the genome that encode proteins. In this study, large …
DR-023 Dynamic response assessments to understand responses to immunotherapy in metastatic cancer
The response to checkpoint inhibitors (immunotherapy) is highly variable between tumor types. The researchers will search for novel biomarkers based …
DR-022 Comprehensive analysis of mutational signatures in metastatic cancers
The DNA in normal – and tumor cells are continuously exposed to internal and external challenges. The objective of this …
DR-021 Targetable yield of whole genome sequencing for glioblastoma
The goal is to investigate the presence of actionable biomarkers in whole genome sequencing (WGS) data of glioblastoma cases and …
DR-019 A comprehensive comparison fo the whole genome sequencing landscape between primary and metastatic cancer tumors
The goal of this study is to systematically compare the mutation landscape and underlying mutagenic mechanisms that are active in …
DR-018 The characterization of homologous recombination deficiency in cancer
Deficiency in DNA repair pathways is a key characteristic in many tumors. The goal of this project is to develop …
DR-017 Identification of non-coding mutations across cancer types
Most studies have focused on mutations in the few percent of the genome that encode proteins. In this study, large …
Gegevens vastleggen en uitwisselen is essentieel voor goede zorg.